John Leonard, CFA
Special situations, micro-cap, contrarian, CFA

SurModics Undervalued And Growing Fast

SurModics (NASDAQ:SRDX) is undervalued relative to its peer group despite a large cash balance, no debt, strong free cash flow and favorable growth prospects.

Company overview

SRDX provides coating technologies that improve drug and device delivery as well as products and technologies for diagnostic test kits and biomedical research applications. Its coatings are used every day in minimally invasive procedures while over half of the top 10 in vitro diagnostic companies are SRDX customers.

SRDX generates revenue from three primary sources:

Royalties and license fees related to drug delivery and surface modification technologies and in vitro diagnostic formats.

Sale of reagent chemicals to licensees as well as stabilization products, antigens, substrates and surface coatings to the diagnostic and...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details